Zymeworks Valuation Multiples

Zymeworks Overview

About Zymeworks

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Founded

2003

HQ

Employees

286

Website

zymeworks.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $147M

EBITDA: ($66M)

EV

$2B

Valuation Multiples

Multiples.vc

Start free trial

Zymeworks Financials

Zymeworks reported last 12-month revenue of $147M and negative EBITDA of ($66M).

In the same LTM period, Zymeworks generated ($66M) in EBITDA losses and had net loss of ($49M).

Zymeworks P&L

In the most recent fiscal year, Zymeworks reported revenue of $106M and EBITDA of ($81M).

Zymeworks expects next 12-month revenue of XXX and NTM EBITDA of XXX

Zymeworks Stock Performance

Zymeworks has current market cap of $2B, and enterprise value of $2B.

Zymeworks' stock price is $25.23.

Zymeworks Valuation Multiples

Zymeworks trades at 11.4x EV/Revenue multiple, and (25.4x) EV/EBITDA.

Zymeworks Financial Valuation Multiples

As of March 21, 2026, Zymeworks has market cap of $2B and EV of $2B.

Equity research analysts estimate Zymeworks' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Zymeworks has a P/E ratio of (38.8x).

Zymeworks Margins & Growth Rates

Zymeworks' revenue in the last 12 month grew by 88%.

Zymeworks' revenue per employee in the last FY averaged $0.5M.

Zymeworks' rule of 40 is 43% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Zymeworks' rule of X is 174% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Zymeworks Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Zymeworks M&A Activity

Zymeworks acquired XXX companies to date.

Last acquisition by Zymeworks was on XXXXXXXX, XXXXX. Zymeworks acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Zymeworks Investment Activity

Zymeworks invested in XXX companies to date.

Zymeworks made its latest investment on XXXXXXXX, XXXXX. Zymeworks invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).